Orchid Pharma (ORCHPHARMA) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 total income was INR 227 crores with EBITDA at INR 37 crores; nine-month FY25 income reached INR 710 crores, up 15% year-over-year, and EBITDA at INR 115 crores, up from INR 99 crores.

• PAT for nine months improved 26% to INR 78 crores from INR 62 crores year-over-year.

• Q3 FY25 PAT at INR 24 crores, down 23% year-over-year; Q3 sales at INR 217 crores, down 2% year-over-year.

• Focus remains on execution, cost optimization, and maintaining healthy margins amid market realignment and price corrections in key products.

• Board approved unaudited standalone and consolidated financial results for Q3 FY2024-25, reviewed by statutory auditors and Audit Committee.

Financial highlights

• Nine-month FY25 total income: INR 710 crores (+15% YoY); EBITDA: INR 115 crores (vs. INR 99 crores YoY); PAT: INR 78 crores (vs. INR 62 crores YoY, +26%).

• Q3 FY25 total income: INR 227 crores; EBITDA: INR 37 crores; PAT: INR 24 crores.

• Gross margin for 9M FY25 at 41%, stable year-over-year.

• Other income for Q3 FY25 at INR 10 crores, up 43% year-over-year.

• Royalty income from Europe received, with growth expected in coming quarters.

Outlook and guidance

• Management expects long-term 20% CAGR in core business over a three-year horizon, but does not provide short-term quarterly guidance.

• Gross margin guidance remains stable at 40% ±2% in the near term.

• EBITDA margin expected to expand by 100 basis points annually due to volume and productivity gains.

• Delays in project implementation for Jammu manufacturing facility and Alathur API block due to land acquisition and regulatory processes.

• AMS division expected to remain EBITDA negative for another year, with break-even anticipated after that.